<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573636</url>
  </required_header>
  <id_info>
    <org_study_id>PCS VIII</org_study_id>
    <nct_id>NCT02573636</nct_id>
  </id_info>
  <brief_title>The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy</brief_title>
  <official_title>The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients With Biochemical Failure Status Post Salvage or Radical Radiation Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and&#xD;
      PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after&#xD;
      biochemical failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and&#xD;
      PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after&#xD;
      biochemical failure.&#xD;
&#xD;
      Patients in this study will be treated with standard hormonal treatment. Patients will remain&#xD;
      on treatment regardless of rising PSA. PSA, other systemic therapy maybe added and the&#xD;
      patients with oligometastasis could be treated with radiation therapy; this would be at the&#xD;
      discretion of the treating oncologist.&#xD;
&#xD;
      The primary endpoint of this study is to determine the predictive value of TMPRSS2-ERG gene&#xD;
      fusion and PTEN in hormonal refractory free survival and clinical progression rate in three&#xD;
      years. The secondary endpoints are to evaluate the relation between Gleason score and&#xD;
      TMPRSS2-ERG gene fusion and PTEN independently and together, the relation between T stage and&#xD;
      TMPRSS2-ERG gene fusion and PTEN independently and together, and to determine the association&#xD;
      of these markers with overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2016</start_date>
  <completion_date type="Anticipated">March 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with biochemical failure showing coexistence of PTEN and TMPRSS2-ERG gene fusion.</measure>
    <time_frame>recruitment over 4 years</time_frame>
    <description>Biopsy samples of patients treated for high risk prostate cancer with radical radiation and hormonal therapy (LHRH) who have either clinical progression or 3-year hormonal refractory free survival will be tested to evaluate the predictive value of the coexistence of TMPRSS2-ERG gene fusion and the PTEN deletion. The results between the two groups will be compared to see if either DNA changes are an indicator of LHRH refractoriness</description>
  </primary_outcome>
  <enrollment type="Anticipated">208</enrollment>
  <condition>Prostate Cancer</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Areas of prostate tumor will be identified by the pathologist of the study. This will then be&#xD;
      excised from the paraffin block using a tissue microarray punch. Two punches will be&#xD;
      acquired: one for RNA extraction and one for DNA extraction. RNA and DNA will be extracted&#xD;
      using the RecoverAll Nucleic Acid Isolation Kit (Ambion). Standard protocol for the isolation&#xD;
      of nucleic acids will be used differing only in the time of protease digestion such that RNA&#xD;
      is isolated after a short incubation (30 minutes), while DNA is isolated after a longer&#xD;
      incubation (overnight). DNA will be used to assess copy number variation at the PTEN locus&#xD;
      (10q23) using quantitative PCR and appropriate Taqman chemistry.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The original slides of 208 patients with informed consent will be reviewed. Patients with&#xD;
        and without markers under the investigation will be accrued into this study. The&#xD;
        investigators at the treating institutions will submit paraffin-embedded tissue blocks from&#xD;
        the original pre-treatment diagnostic prostatic biopsy, which will be reviewed to confirm&#xD;
        the Gleason score and to record other histopathologic features, such as the extent of tumor&#xD;
        in the biopsies, the number of positive biopsies, and mitotic index.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  T3a +&#xD;
&#xD;
          -  PSA &gt; 20&#xD;
&#xD;
          -  Gleason 8 or higher&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70.&#xD;
&#xD;
          -  Signed study-specific informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ashley Feng, M.Sc.</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>26510</phone_ext>
    <email>yanqi.feng.ccomtl@ssss.gouv.qc.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi</name>
      <address>
        <city>Chicoutimi</city>
        <state>Quebec</state>
        <zip>G7H 5H6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hugo Villeneuve, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne</name>
      <address>
        <city>Greenfield Park</city>
        <state>Quebec</state>
        <zip>J4V 2H1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Genevieve Bujold</last_name>
    </contact>
    <investigator>
      <last_name>Marjorie Jolicoeur, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval</name>
      <address>
        <city>Laval</city>
        <state>Quebec</state>
        <zip>H7M 3L9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Tremblay</last_name>
    </contact>
    <investigator>
      <last_name>Levon Igidbashian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josée Abi-Saad</last_name>
    </contact>
    <investigator>
      <last_name>Peter Vavassis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital, McGill University</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Feng, M.Sc.</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>26510</phone_ext>
      <email>yanqi.feng.ccomtl@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Tamim Niazi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MUHC - Cedars Cancer Center</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Perna</last_name>
    </contact>
    <investigator>
      <last_name>Luis Souhami, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
    </contact>
    <investigator>
      <last_name>Abdenour Nabid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8Z 3R9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Eve Caron</last_name>
    </contact>
    <investigator>
      <last_name>Linda-Suzanne Vincent, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU - L'Hôtel-Dieu de Québec</name>
      <address>
        <city>Quebec</city>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josée Allard</last_name>
    </contact>
    <investigator>
      <last_name>André-Guy Martin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 5, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>October 19, 2020</last_update_submitted>
  <last_update_submitted_qc>October 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Tamim Niazi</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

